G31P, CXCR1/2 inhibitor, with cisplatin inhibits the growth of mice hepatocellular carcinoma and mitigates high-dose cisplatin-induced nephrotoxicity

Oncology Reports

Volumn 33, Issue 2, 2015, Pages 751-757

  Li, Lingyun ^a,b   Khan, Muhamad Noman ^a   Li, Qiang ^c   Chen, Xiangyu ^b   Wei, Jing ^a   Wang, Bing ^a   Cheng, Jya Wei ^d   Gordon, John R ^e   Li, Fang ^a  

^a DALIAN MEDICAL UNIVERSITY   (China)

^b HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

^c JILIN MEDICAL COLLEGE   (China)

^d NATIONAL TSING HUA UNIVERSITY   (Taiwan)

^e ROYAL UNIVERSITY HOSPITAL   (Canada)

Author keywords

Cisplatin; CXCR1 2; G31P; Mice hepatocarcinoma; Nephrotoxicity

Indexed keywords

CHEMOKINE RECEPTOR CCR ANTAGONIST; CISPLATIN; CREATININE; EPIDERMAL GROWTH FACTOR RECEPTOR; G31P; GELATINASE A; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MACROPHAGE INFLAMMATORY PROTEIN 2; MYELOPEROXIDASE; NITROGEN; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; UREA; VASCULOTROPIN; ANTINEOPLASTIC AGENT; CXCL8(3-73)K11R,G31P; CYTOKINE; INTERLEUKIN 8; PEPTIDE FRAGMENT;

ACUTE KIDNEY FAILURE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIPROLIFERATIVE ACTIVITY; ARTICLE; BAGG ALBINO MOUSE; CANCER INHIBITION; CONTROLLED STUDY; CREATININE BLOOD LEVEL; CYTOKINE RELEASE; DRUG EFFICACY; DRUG MEGADOSE; DRUG POTENTIATION; FEMALE; HISTOPATHOLOGY; IN VITRO STUDY; IN VIVO STUDY; LIVER CANCER CELL LINE; LIVER CELL CARCINOMA; MOUSE; NEPHROTOXICITY; NEUTROPHIL CHEMOTAXIS; NONHUMAN; PROTEIN EXPRESSION; SINGLE DRUG DOSE; SURVIVAL RATE; UREA NITROGEN BLOOD LEVEL; ANIMAL; CARCINOMA, HEPATOCELLULAR; CELL PROTECTION; CHEMICALLY INDUCED; DRUG EFFECTS; GENETICS; KIDNEY DISEASES; LIVER NEOPLASMS; METABOLISM; TUMOR CELL LINE;

ANIMALS; ANTINEOPLASTIC AGENTS; CARCINOMA, HEPATOCELLULAR; CELL LINE, TUMOR; CISPLATIN; CYTOKINES; CYTOPROTECTION; DRUG SYNERGISM; FEMALE; INTERLEUKIN-8; KIDNEY DISEASES; LIVER NEOPLASMS; MICE; MICE, INBRED BALB C; PEPTIDE FRAGMENTS;

EID: 84919456495     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.2014.3659     Document Type: Article

References (30)

1. Forner A, Llovet JM and Bruix J: Hepatocellular carcinoma. Lancet 379: 1245-1255, 2012.
2. Shen FZ, Wang J, Liang J, Mu K, Hou JY and Wang YT: Low-dose metronomic chemotherapy with cisplatin: can it suppress angioGenesis in H22 hepatocarcinoma cells? Int J Exp Pathol 91: 10-16, 2010.
3. Ozdogan O, Ertay T, Arslan G, et al: Does cisplatin chemotherapy decrease the MDP uptake of normal bone? An experimental study. Ann Nucl Med 22: 357-362, 2008.
4. Arany I and Safirstein RL: Cisplatin nephrotoxicity. Semin Nephrol 23: 460-464, 2003.
5. Bonventre JV: Pathophysiology of ischemic acute renal failure. Infammation, lung-kidney cross-talk, and biomarkers. Contrib Nephrol 144: 19-30, 2004.
6. Ramesh G and Reeves WB: TNFR2-mediated Apoptosis and necrosis in cisplatin-induced acute renal failure. Am J Physiol Renal Physiol 285: 610-618, 2003.
7. Faubel S, Lewis EC, Reznikov L, Ljubanovic D, Hoke TS, Somerset H, Oh DJ, Lu L, Klein CL, Dinarello CA and Edelstein CL: Cisplatin-induced acute renal failure is associated with an increase in the cytokines interleukin (IL)-1β, IL-18, IL-6, and neutrophil infltration in the kidney. J Pharmacol and Exp Ther 322: 8-15, 2007.
8. Mukaida N: Pathophysiological roles of interleukin-8/CXCL8 in pulmonary diseases. Am J Physiol Lung Cell Mol Physiol 284: L566-L577, 2003.
9. Wang Y, Wang W, Wang L, Wang X and Xia J: Regulatory mechanisms of interleukin-8 production induced by tumor necrosis factor-α in human hepatocellular carcinoma cells. J Cell Mol Med 16: 496-506, 2012.
10. (3-74)K11R/G31P, effectively block ELR-CXC chemokine activity and airway endotoxemia pathology. Int Immunopharmacol 7: 1723-1731, 2007.
11. Zhao X, Town JR, Li F, Zhang X, Cockcroft DW and Gordon JR: ELR-CXC chemokine receptor antagonism targets infammatory responses at multiple levels. J Immunol 182: 3213-3222, 2009.
12. (3-74)K11R/G31P blocks neutrophil infltration, pyrexia, and pulmonary vascular pathology in endotoxemic animals. J Leukoc Biol 78: 1265-1272, 2005.
13. Zhao X, Town JR, Li F, Li W, Zhang X and Gordon JR: Blockade of neutrophil responses in aspiration pneumonia via ELR-CXC chemokine antagonism does not predispose to airway bacterial outgrowth. Pulm Pharmacol Ther 23: 22-28, 2010.
14. Zhao X, Town JR, Yang A, Zhang X, Paur N, Sawicki G and Gordon JR: A novel ELR-CXC chemokine antagonist reduces intestinal ischemia reperfusion-induced mortality, and local and remote organ injury. J Surg Res 162: 264-273, 2010.
15. Liu X, Peng J, Sun W, Yang S, Deng G, Li F, Cheng JW and Gordon JR: G31P, an antagonist against CXC chemokine receptors 1 and 2, inhibits growth of human prostate cancer cells in nude mice. Tohoku J Exp Med 228: 147-156, 2012.
16. Qin Y, Fan F, Zhao Y, Cui Y, Wei X, Kohama K, Gordon JR, Li F and Gao Y: Recombinant human CXCL8 (3-72) K11R/G31P regulates smooth muscle cell proliferation and migration through blockage of interleukin-8 receptor. IuBMB Life 65: 67-75, 2013.
17. Wei J, Peng J, Wang B, Qu H, Wang S, Faisal A, Cheng J W, Gordon JR and Li F: CXCR1/CXCR2 antagonism is effective in pulmonary defense against Klebsiella pneumoniae infection. Biomed Res Int 2013: 720975, 2013.
18. Shen DW, Pouliot LM, Hall MD and Gottesman MM: Cisplatin resistance: a cellular self-defense mechanism resulting from multiple epigenetic and genetic changes. Pharmacol Rev 64: 706-721, 2012.
19. Friedewald JJ and Rabb H: Infammatory cells in ischemic acute renal failure. Kidney Int 66: 486-491, 2004.
20. Okusa MD: The infammatory cascade in acute ischemic renal failure. Nephron 90: 133-138, 2002.
21. Wang W, Qin SK, Chen BA and Chen HY: Experimental study on antitumor effect of arsenic trioxide in combiNation with cisplatin or doxorubicin on hepatocellular carcinoma. World J Gastroenterol 7: 702-705, 2001.
22. Yuan A, Chen JJ, Yao PL and Yang PC: The role of interleukin-8 in cancer cells and microenvironment interaction. Front Biosci 10: 853-865, 2005.
23. Xie K: Interleukin-8 and human cancer biology. Cytokine Growth Factor Rev 12: 375-391, 2001.
24. Harimoto N, Shirabe K, Abe T, et al: Interleukin-8 producing hepatocellular carcinoma with pyrexia. HPB Surg 1: 461-492, 2009.
25. Yoong KF, Afford SC, Jones R, Aujla P, Qin S, Price K, Hubscher SG and Adams DH: Expression and function of CXC and CC chemokines in human malignant liver tumors: a role for human monokine induced by gamma-interferon in lymphocyte recruitment to hepatocellular carcinoma. Hepatology 30: 100-111, 1999.
26. Yang ZF and Poon RT: Vascular changes in hepatocellular carcinoma. ANat Rec 291: 721-734, 2008.
27. Tanaka H, Yamamoto M, Hashimoto N, Miyakoshi M, Tamakawa S, Yoshie M, Okusashi Y, Yokoyama K, Yaginuma Y and Ogawa K: Hypoxia-independent overexpression of hypoxia-inducible factor 1α as an early change in mouse hepato-carcinoGenesis. Cancer Res 66: 11263-11270, 2006.
28. Luppi F, Longo AM, De Boer WI, Rabe KF and Hiemstra PS: Interleukin-8 stimulates cell proliferation in non-small cell lung cancer through epidermal growth factor receptor transactivation. Lung Cancer 56: 25-33, 2007.
29. Wu Y and Zhou BP: TNF-α/NF-κB/Snail pathway in cancer cell migration and invasion. Br J Cancer 102: 639-644, 2010.
30. Guilpain P, Servettaz A, Batteux F, Guillevin L and Mouthon L: Natural and disease associated anti-myeloperoxidase (MPO) autoantibodies. Autoimmun Rev 7: 421-425, 2008.